Zealand Pharma (ZEAL.CO) Presented New Data On Two Novel Peptide Therapeutics From Its Preclinical Diabetes Pipeline At The American Diabetes Association 74th Scientific Sessions
6/17/2014 9:01:57 AM
Copenhagen, 17 June 2014 – Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) informs of new data presented on two flagship peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions, taking place 13-17 June in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
comments powered by